| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 2603.5 | 2149.8 | 1910.2 |
| Other income | 15.1 | 14.9 | 6.9 |
| Total income | 2618.6 | 2164.7 | 1917.1 |
| Profit before exceptional items & tax | 437.9 | 221.9 | 223.7 |
| Profit before tax | 437.9 | 221.9 | 223.7 |
| Net profit | 335.2 | 173.1 | 184.7 |
| Operating margin | 16.7% | 10.3% | 11.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +81.50% |
|---|---|
| Net profit, quarter on quarter | +93.60% |
| Revenue, year on year | +36.30% |
| Operating profit, year on year | +95.00% |
| Operating profit, quarter on quarter | +104.30% |
BSE results filing, NSE: APLLTD. Figures extracted from the filing.
Alembic Pharmaceuticals Ltd: key numbers
- Share price
- ₹836.20
- Market cap
- ₹16,437 Cr
- Revenue (annual)
- ₹7,345 Cr
- Net profit (annual)
- ₹674.8 Cr
- P/E (TTM)
- 23.7×Sector 41.3×
- Promoter holding
- 69.87%+0.00% QoQ
- FII holding
- 4.55%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alembic Pharmaceuticals Ltd
All →Alembic Pharmaceuticals Other Announcement
Alembic Pharmaceuticals Limited has updated its list of Key Managerial Personnel authorised to determine materiality and make stock exchange disclosures. This update follows a board meeting held on November 4, 2026.
Alembic Pharmaceuticals Partnership
Alembic Pharmaceuticals expanded its strategic collaboration with DifGen Pharmaceuticals to commercialize over 20 complex generic products in the US. The portfolio targets a US$5 billion market.
- From
- DifGen Pharmaceuticals
- Execution
- Initial launches from FY28
Alembic Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹26.03bn (+36% YoY), PAT ₹3.35bn (+81%), EBITDA margin 22% (+520bps). US formulations led growth (+77%).
Alembic Pharmaceuticals Results Update
Alembic Pharmaceuticals reported Q2 FY27 revenue growth of 36% to ₹2,603 Crore. Net profit surged 81% to ₹335 Crore, driven by exceptional US business performance.
- Value
- ₹2,603 Cr
Alembic Pharmaceuticals Board Meeting Date
Alembic Pharmaceuticals scheduled its board meeting for November 4, 2026, to consider unaudited Q1/H1 FY27 results. Trading window re-opens 48 hours post-declaration.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.